ClinicalTrials.gg
WithdrawnNCT07626476Updated Oct 13, 2026

Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis

An Early Phase 1 interventional study of Targeted BCMA Autologous CART Cell Injection in Relapsed/Refractory Light Chain Amyloidosis, AL Amyloidosis and Systemic Light Chain Amyloidosis, sponsored by Beijing Boren Hospital. Withdrawn at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Beijing Boren Hospital · Early Phase 1, Interventional, and Treatment

How we know

Why this study was withdrawn
Due to the promulgation of State Council Order No. 818, clinical trials of this category are prohibited.

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Dec 2024, registered May 2026).
Updated Oct 13, 2026Now WithdrawnEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Immunoglobulin Light-chain Amyloidosis with a site in China — 19 open to participants now, 21 under way, 2 of them phase 3. Immunoglobulin Light-chain Amyloidosis · China.

Enrollment
23rd of 24
0 · median 36
Started
2024
with 5 others
Phase 1
4 of 29
2 open now
Registered
27th of 29
by date
Lead sponsor
2 of 29
Beijing Boren Hospital

Among the 29 studies in Immunoglobulin Light-chain Amyloidosis with a site in China, this one is the 23rd largest by enrollment of the 24 interventional ones that give a count, is one of 6 that started in 2024, is one of 4 in phase 1, and was the 27th registered.

Immunoglobulin Light-chain Amyloidosis

239 studies on the registry are indexed under Immunoglobulin Light-chain Amyloidosis; 63 are open to participants now.

Browse Immunoglobulin Light-chain Amyloidosis studies →

Open to participants now

19 of the 29 studies in Immunoglobulin Light-chain Amyloidosis with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 49 Immunoglobulin Light-chain Amyloidosis studies recruiting now, 34 (69%) set no upper age limit and 3 (6%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Immunoglobulin Light-chain Amyloidosis with a site in China, or all of them as a file.
02

Study summary

Systemic light chain amyloidosis (AL amyloidosis) is the most common type of systemic amyloidosis, with diverse clinical manifestations and difficulties in diagnosis and treatment. AL amyloidosis may involve multiple organs; the kidney and heart are the most commonly involved organs. The treatment goal is to reduce monoclonal immunoglobulin light-chain levels, prevent further amyloid deposition in important organs, and alleviate or reverse organ dysfunction caused by amyloid deposition. The principal approach to achieve this goal is to eliminate the plasma-cell or B-cell clones producing abnormal light chains. For patients with relapsed/refractory AL amyloidosis, the protocol states that there is currently no suitable treatment method and that participation in clinical trials is recommended.

This study evaluates targeted BCMA autologous CART cell injection in participants with relapsed/refractory light chain amyloidosis. The main purpose is to evaluate safety, preliminarily verify efficacy, and explore in vivo pharmacokinetics, pharmacodynamics, immunogenicity and related characteristics after infusion.

Read the detailed description

This is an open-label, fixed-dose exploratory clinical study to observe the safety and efficacy of targeted BCMA autologous CART cell injection in participants with relapsed/refractory light chain amyloidosis. The study is expected to enroll 30 participants and uses a fixed dose of 1.0×10\^6 CAR-T/kg. The safety observation period is 28 days after CAR-T administration.

The study process includes screening, PBMC leukapheresis, pre-lymphodepletion examination, lymphodepleting conditioning, infusion of targeted BCMA autologous CART cell injection with the infusion day defined as Day 0, and the main follow-up period.

Before infusion, participants receive fludarabine plus cyclophosphamide lymphodepleting conditioning from Day -5 to Day -3 for three consecutive days. The recommended regimen is cyclophosphamide 250 mg/m²/day by intravenous infusion once daily for three days and fludarabine 25 mg/m²/day by intravenous infusion once daily for three days. The investigator may adjust the conditioning regimen according to renal function and creatinine clearance, such as replacing fludarabine with bendamustine or reducing the dose.

The targeted BCMA autologous CART cell injection is infused once on Day 0 by intravenous injection and completed within 30 minutes. If an adverse event occurs after conditioning and before infusion and the investigator determines that infusion should be suspended, infusion may be delayed until the adverse event recovers to a state allowing infusion. Before infusion, the investigator should reassess whether repeated lymphodepleting conditioning is needed.

The main follow-up period lasts from infusion of targeted BCMA autologous CART cell injection until the participant meets the criteria for exit from main follow-up or completes the 2-year main follow-up visit at Day 720. Efficacy assessments are performed at Day 28, Day 60 and Day 90, and then every 90 days until the end of main follow-up. Participants who complete the 2-year main follow-up enter long-term follow-up. Participants who meet criteria to exit main follow-up enter long-term visits until death, withdrawal from the study, or 15 years after cell infusion.

03

Conditions studied

  • Relapsed/Refractory Light Chain Amyloidosis
  • AL Amyloidosis
  • Systemic Light Chain Amyloidosis

Keywords

  • AL amyloidosis
  • light chain amyloidosis
  • relapsed/refractory
  • BCMA
  • CAR-T
  • autologous CAR-T
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant must personally sign an ethics-committee-approved form before study start.
  • Age ≥18 years.
  • confirmed light chain amyloidosis.
  • light chain amyloidosis previously treated with 2 or more .
  • dFLC >50 mg/L.
  • Expected survival ≥12 weeks.
  • score ≤2.
  • Diagnosis of AL amyloidosis must meet the following conditions: (1) clinical manifestations, physical examination, laboratory or imaging examinations confirm tissue or organ involvement; (2) tissue pathology confirms amyloid deposition, and the precursor protein of amyloid protein is immunoglobulin light chain or heavy and light chain; and the participant is relapsed/refractory.
  • Female participants of should agree to use effective from the date of signing informed consent until 365 days after infusion. Effective contraception is defined as abstinence or contraception using methods specified in the protocol with an annual failure rate \<1%.
  • Adequate organ function before enrollment, meeting all of the following:

    • ≥1.0×10\^9/L; granulocyte colony-stimulating factor (G-CSF) support is permitted.
    • count ≥50×10\^9/L.
    • ≥8 g/dL.
    • ≤1.5× (ULN), except biliary obstruction caused by tumor compression.
    • or AST ≤2.5×ULN; for participants with liver involvement, ≤5×ULN.
    • Mayo 2004 stage I-IIIa.
    • Stable coagulation function: ≤1.5 and APTT ≤1.2×ULN, except tumor-related anticoagulant therapy.
    • Baseline oxygen saturation on room air >92%.

Exclusion criteria

Exclusion Criteria:

  • Participants who have received the following prior treatments:

    • Prior gene therapy before enrollment.
    • injection within 4 weeks before enrollment.
    • Other interventional clinical study drug treatment within 12 weeks before leukapheresis.
  • Central nervous system involvement or complete intestinal obstruction.
  • Moderate or higher pleural effusion or ascites that is difficult to control with conventional treatment and requires continuous catheter drainage.
  • Active within the past 5 years, unless it is a curable tumor and has been clearly cured.
  • positivity with abnormal peripheral blood HBV DNA testing; antibody positivity with peripheral blood HCV RNA positivity; antibody positivity; CMV DNA positivity; or positive syphilis RPR test.
  • Uncontrolled active infection, except grade \<2 urogenital infection and upper respiratory tract infection.
  • Severe heart disease, including but not limited to unstable angina, myocardial infarction within 6 months before screening, congestive heart failure ( [NYHA] class ≥III), positive six-minute walk test, interventricular septum and left ventricular posterior wall thickness >1.5 cm, or ventricular arrhythmia and atrioventricular block indicated by ambulatory electrocardiography.
  • Hypertension that cannot be controlled by medication.
  • Toxicity from prior treatment not recovered to baseline or ≤grade 1 according to NCI CTCAE v5.0, except alopecia and clinically insignificant laboratory abnormalities.
  • Major surgery within 2 weeks before enrollment, or planned surgery during the waiting period before infusion or within 12 weeks after study treatment, except planned local anesthesia surgery.
  • Solid organ transplantation.
  • Pregnant or breastfeeding women.
  • History of central nervous system disease, such as cerebral aneurysm, epilepsy, stroke, senile dementia or psychiatric disease, or disturbance of consciousness.
  • Other systemic disease judged unstable by the investigator, including but not limited to severe hepatic, renal or metabolic disease requiring medication.
  • Known life-threatening allergic reaction, or intolerance to the CAR-T cell product or its components.
  • Bleeding or severe thrombosis as judged by the investigator, hereditary/acquired bleeding or severe thrombosis, including hemophilia, coagulopathy, thrombocytopenia and hypersplenism, or current thrombolytic or anticoagulant therapy.
  • Other conditions that the investigator considers unsuitable for enrollment.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Autologous BCMA-targeted CAR-T Cell Injection

    Targeted BCMA autologous CART cell injection at a fixed dose of 1.0×10\^6 CAR-T/kg.

    Biological: Targeted BCMA Autologous CART Cell Injection

Interventions

  • BiologicalTargeted BCMA Autologous CART Cell Injection

    Anti-BCMA chimeric antigen receptor autologous T cells are a BCMA-targeted, gene-modified autologous T-cell (CAR-T cell) immunotherapy derived from the participant's autologous peripheral blood mononuclear cells (PBMCs). The cells are transduced with lentivirus generated using a four-plasmid viral packaging system, with the pCDH-BCMA CAR plasmid as the expression vector. The product is administered as an injection by a single intravenous infusion at a dose of 1.0×10\^6 CAR-T cells/kg.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest

    The number and percentage of participants with adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs) will be summarized. AEs and SAEs will be summarized by system organ class (SOC), preferred term (PT), severity, seriousness, relationship to study treatment, and outcome. AESIs include Grade 3 or higher hematologic toxicity lasting more than 30 days, excluding lymphocytopenia; hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS); Grade 3 or higher infections; uncontrolled CAR-T cell expansion; Grade 3 or higher cytokine release syndrome (CRS); Grade 3 or higher immune effector cell-associated neurotoxicity syndrome (ICANS); progressive multifocal leukoencephalopathy; secondary malignancies; and detection of replication-competent lentivirus (RCL). AEs other than CRS and ICANS will be graded per NCI-CTCAE Version 5.0; CRS and ICANS will be graded per 2019 ASTCT criteria.

    Time frame: From signing of the informed consent form through withdrawal from the study or 2 years after BCMA-targeted autologous CAR-T cell infusion, whichever occurs first.

Secondary outcomes

  1. Objective response rate (ORR)

    Proportion of participants whose best efficacy evaluation within 6 months after infusion of BCMA-targeted Autologous CAR-T Cell Injection is partial response (PR) or complete response (CR), according to the National Comprehensive Cancer Network (NCCN) 2023 guideline and evaluation criteria for systemic light-chain amyloidosis.

    Time frame: Within 6 months after infusion.

  2. Duration of response (DoR)

    Time from the first efficacy evaluation of complete response (CR) or partial response (PR) to the first efficacy evaluation of progressive disease (PD)/relapse or death due to the study disease.

    Time frame: From the first efficacy evaluation of CR/PR until the first efficacy evaluation of PD/relapse or death due to the study disease, assessed until exit from main follow-up or completion of the Day 720 visit.

  3. Time to response (TTR)

    Time from infusion of BCMA-targeted Autologous CAR-T Cell Injection to the first efficacy evaluation of partial response (PR) or complete response (CR).

    Time frame: From infusion until the first efficacy evaluation of PR or CR, assessed until exit from main follow-up or completion of the Day 720 visit.

  4. Progression-free survival (PFS)

    Time from infusion of BCMA-targeted Autologous CAR-T Cell Injection to the first efficacy evaluation showing disease progression/relapse or death from any cause.

    Time frame: From infusion until the first disease progression/relapse or death from any cause, assessed until exit from main follow-up or completion of the Day 720 visit.

  5. Overall survival (OS)

    Time from infusion of BCMA-targeted Autologous CAR-T Cell Injection to death from any cause.

    Time frame: From infusion until death from any cause, assessed until exit from main follow-up or completion of the Day 720 visit.

  6. Changes in peripheral blood viral vector copy number (VCN) levels

    Peripheral blood BCMA-CAR viral vector copy number (VCN) is quantitatively detected by PCR.

    Time frame: Day -12 to -5 before infusion (no later than 1 minute before lymphodepletion); Days 1 and 4 (±8 h), Days 7 and 10 (±1 d), Days 14 and 21 (±2 d), Day 28 (±3 d), Days 60 and 90 and every 90 days thereafter (±14 d) through Day 720.

  7. Changes in peripheral blood CAR-T cell concentration levels

    Peripheral blood BCMA-positive CAR-T cells are detected by flow cytometry.

    Time frame: Day -12 to -5 before infusion (no later than 1 minute before lymphodepletion); Days 1 and 4 (±8 h), Days 7 and 10 (±1 d), Days 14 and 21 (±2 d), Day 28 (±3 d), Days 60 and 90 and every 90 days thereafter (±14 d) through Day 720.

  8. Maximum concentration (Cmax)

    Maximum concentration of peripheral blood BCMA-CAR VCN and BCMA-positive CAR-T cells after infusion of BCMA-targeted Autologous CAR-T Cell Injection.

    Time frame: Calculated from PK assessments conducted from pre-infusion sampling through the last PK assessment during main follow-up, up to Day 720 after infusion.

  9. Time to maximum concentration (Tmax)

    Time to reach the maximum concentration of peripheral blood BCMA-CAR VCN and BCMA-positive CAR-T cells after infusion of BCMA-targeted Autologous CAR-T Cell Injection.

    Time frame: Calculated from PK assessments conducted from pre-infusion sampling through the last PK assessment during main follow-up, up to Day 720 after infusion.

  10. Area under the curve from Day 0 to Day 28 (AUC0-28d)

    Area under the concentration-time curve of peripheral blood BCMA-CAR VCN and BCMA-positive CAR-T cells from Day 0 to Day 28 after infusion.

    Time frame: From Day 0 through Day 28 after infusion.

  11. Area under the curve from Day 0 to Day 90 (AUC0-90d)

    Area under the concentration-time curve of peripheral blood BCMA-CAR VCN and BCMA-positive CAR-T cells from Day 0 to Day 90 after infusion.

    Time frame: From Day 0 through Day 90 after infusion.

  12. Area under the curve from Day 0 to the last PK assessment (AUC0-last)

    Area under the concentration-time curve of peripheral blood BCMA-CAR VCN and BCMA-positive CAR-T cells from Day 0 to the last PK assessment time point.

    Time frame: From Day 0 through the last PK assessment during main follow-up, up to Day 720 after infusion.

07

Study locations

1 site
  • Beijing GoBroad Boren Hospital
    Beijing, Fengtai District 100070, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Dec 2027, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2026
First posted
Jun 4, 2026
StartActual
Dec 16, 2024
Primary completionEst.
Dec 15, 2027
CompletionEst.
Dec 15, 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Withdrawn Due to the promulgation of State Council Order No. 818, clinical trials of this category are prohibited.
changed Oct 13, 2026
Enrollment
30 (estimated)→0 (actual)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Recruiting→Withdrawn
    Why stopped Due to the promulgation of State Council Order No. 818, clinical trials of this category are prohibited.
    Enrollment 30 (estimated)→0 (actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07626476
Lead sponsor
Beijing Boren Hospital
Responsible party
Sponsor
First posted
Jun 4, 2026
Start date
Dec 16, 2024
Primary completion
Dec 15, 2027 (estimated)
Completion
Dec 15, 2029 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion